Brean Murray Carret & Co. Maintains a 'Buy' on Achillion Pharmaceuticals (ACHN); Becoming Top Hec C Play
Tweet Send to a FriendGet Alerts ACHN Hot Sheet
Price: $7.75 +2.65%
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade ACHN Now!
Brean Murray Carret & Co. maintains a 'Buy' on Achillion Pharmaceuticals (NASDAQ: ACHN) price target of $20.00.
Analyst, Brian Skorney, said, "We believe ACHN is positioned, post EASL abstracts, with the most compelling value proposition in the Hep C space. In ACH-1625, Achillion has the asset best positioned to compete with Gilead (Nasdaq: GILD)(Buy-rated) in a race to a once-daily, pan-genotyplic, interferon-free treatment regimen: a one size fits all treatment for all Hep C patients. We believe competitive data clearly indicates that a nuc is not necessary to eliminate interferon from the treatment regimen, provided the asset filling that role is very potent and exhibits a differentiated barrier to resistance. However, we believe it is important that the backbone agent has potent antiviral activity against fit resistant strains. We believe ACH-1625 is one of only a handful of assets that offer the hope of matching this profile."
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $10.47 yesterday, with a 52 week range of $3.81-$12.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Brian Skorney, said, "We believe ACHN is positioned, post EASL abstracts, with the most compelling value proposition in the Hep C space. In ACH-1625, Achillion has the asset best positioned to compete with Gilead (Nasdaq: GILD)(Buy-rated) in a race to a once-daily, pan-genotyplic, interferon-free treatment regimen: a one size fits all treatment for all Hep C patients. We believe competitive data clearly indicates that a nuc is not necessary to eliminate interferon from the treatment regimen, provided the asset filling that role is very potent and exhibits a differentiated barrier to resistance. However, we believe it is important that the backbone agent has potent antiviral activity against fit resistant strains. We believe ACH-1625 is one of only a handful of assets that offer the hope of matching this profile."
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $10.47 yesterday, with a 52 week range of $3.81-$12.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Goldman Sachs Upgrades Meritor (MTOR) to Buy
- Jefferies Raises Numbers on hhgregg (HGG), But Remains on Sidelines
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Brean Murray Carret & Co.Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
about achn
AAAA on Apr 5, 2012 01:11 PMMark as Spam | Reply to this comment
big mistake assumption about achn